- Home
- SOC vs ELVN Comparison
SOC vs ELVN Comparison
Compare SOC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | ELVN |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | 200 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOC | ELVN |
|---|---|---|
| Price | $13.36 | $48.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $19.33 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 4.4M | 1.7M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $234.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $14.79 |
| 52 Week High | $35.00 | $46.31 |
Technical Indicators
Market Signals| Indicator | SOC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 74.97 |
| Support Level | $11.25 | $17.99 |
| Resistance Level | $14.77 | N/A |
| Average True Range (ATR) | 1.27 | 2.66 |
| MACD | -0.39 | 0.40 |
| Stochastic Oscillator | 18.23 | 97.64 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.